BDNF

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog® as Groundbreaking Dietary Supplement for Cognitive Support

Retrieved on: 
Tuesday, March 26, 2024
Function (mathematics), Gallic acid, Attention, Brain, Ellagic acid, Longevity, Growth, Prevalence, Learning, BDNF, Science, Clinical, Memory, Disease, Name, Eternal, Ageing, Brain-derived neurotrophic factor, Marketing, Homocysteine, PLT, Food, Dietary supplement

MORRISTOWN, N.J., March 26, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced BioTRUST Nutrition® LLC, a leading eCommerce-based nutrition brand with a portfolio of high-quality, science-backed products focused on healthy aging and improving healthspan, has introduced a new product targeted at providing brain longevity and cognitive support called Eternal Mind®. The new product features PLT's Nutricog® Cognitive Performance Complex, an ingredient that has been clinically demonstrated to provide significant improvements across multiple cognitive domains, including learning, memory, attention, focus, and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking. In addition, clinical science showed that Nutricog doubled levels brain-derived neurotrophic factor (BDNF), a neuroprotein involved in the brain's ability to adapt to new information.

Key Points: 
  • Eternal Mind is available direct-to-consumer from the BioTRUST Nutrition website ( www.biotrust.com ) and via Amazon.
  • "Brain and cognitive health are a significant concern for many Americans, especially as we age.
  • However, navigating the cognitive supplement market can be challenging due to the prevalence of expensive products with ambiguous 'proprietary blends' and vague claims," Chris Marschall said.
  • According to BioTRUST®, Eternal Mind is backed by the latest science in brain health.

Health Direct Introduces AminoMind, The First-Of-Its-Kind Nootropic Collagen

Retrieved on: 
Thursday, March 14, 2024
Dopamine, Fatigue, Brain, Nutrient, Mevalonate pathway, Learning, Serotonin, Science, BDNF, Memory, Research, Nitric oxide, Neurogenesis, Collagen, Water, Blood, Medical imaging

IRVINE, Calif., March 14, 2024 /PRNewswire/ -- Health Direct, makers of AminoSculpt Liquid Collagen, has released the first-ever nootropic collagen, AminoMind. This new form of liquid collagen contains the clinically documented dosage of Brain-derived Neurotropic Factor (BDNF) building nutrients. BDNF creates new brain cells (neurogenesis) and supports new neural pathways and adaptation (neuroplasticity.)

Key Points: 
  • IRVINE, Calif., March 14, 2024 /PRNewswire/ -- Health Direct, makers of AminoSculpt Liquid Collagen, has released the first-ever nootropic collagen, AminoMind.
  • This new form of liquid collagen contains the clinically documented dosage of Brain-derived Neurotropic Factor (BDNF) building nutrients.
  • CollaBrain's dipeptides are the only collagen clinically shown to improve brain health and support BDNF production.
  • It's about supporting your brain's structure," says Jim Caras, founder of Health Direct, "Imagine pouring very expensive water into a bucket with holes.

Inoviv Launches NeuroKey-3™, A Quantitative Multiplexed IP-MS Assay to Measure Key Low-Level Markers in Neurodegeneration

Retrieved on: 
Friday, March 1, 2024
BDNF, Lipid, FDA, Neuroinflammation, Alzheimer's disease, NRGN, Disease, Biomarker, Protein, Clinical trial, Plasma, Dementia

NeuroKey-3™ is a proprietary method providing absolute quantification of multiple proteins in a single IP-MS assay.

Key Points: 
  • NeuroKey-3™ is a proprietary method providing absolute quantification of multiple proteins in a single IP-MS assay.
  • NeuroKey-3™ is now commercially available through Inoviv for drug developers to gather valuable data for their clinical trials.
  • LONDON, March 1, 2024 /PRNewswire/ -- Biomarker pioneer, Inoviv, announces the launch of its proprietary NeuroKey-3™ assay, an end-to-end service offering to measure key low-level markers in neurodegeneration in human plasma.
  • "NeuroKey-3 provides highly accurate and fully quantitative insights into proteins linked to neurodegeneration and can be adapted to provide definitive data into post-translational modifications, other proteins, lipids, and metabolites."

Pharmactive's Saffron Extract improves Resilience to Occasional Stress

Retrieved on: 
Wednesday, January 24, 2024
DSM-IV codes, Hypothalamus, Arginine, Iterative method, Pituitary gland, Research, Overalls, Manager, Food, Health, Brain-derived neurotrophic factor, HPA, Hormone, Survival, Communication, History, Nutrient, Anxiety, Pandemic, Human, Gland, Doctor of Philosophy, Rat, Anhedonia, ACTH, Adrenocorticotropic hormone, CRF, Brain, Motivation, Glucocorticoid, BDNF, Depression, Growth

MADRID, Jan. 24, 2024 /PRNewswire/ -- A new in vitro study sheds light to the stress relief effect of saffron (Crocus sativus L). The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.

Key Points: 
  • The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.
  • Results demonstrated significant improvements following repeated oral administration of the extract in stress model animal subjects.
  • The HPA axis is a vital brain signaling system involved in orchestrating responses to stress.
  • We are realizing these extend beyond influencing serotonin expression but actually demonstrates a potential to boost resilience to occasional stress and prevent its detrimental impact on overall mental and physical health."

How Technology Can Be a Game Changer in Mental Health Treatment and AI Is Leading the Way

Retrieved on: 
Wednesday, November 22, 2023
FDA, Psychotherapy, Health, DSM-IV codes, B2B, BDNF, News, Serum, USD, Mental health, Talkspace, Neurology, Diagnosis, Neuron, Q3, Couples therapy, Parkinson's disease, Depression, Alzheimer's disease, Artificial intelligence, Chatbot, Decision support system, Food, Conversation, Vitamin D, Firefly, Huntington's disease, Behavior, AI, Patient, Intelligence, Brain-derived neurotrophic factor, Survival, Sale, Research, Mental, My Little Pony, Ferhat Ozcep, Growth

Most medical experts agree we are in a global mental health crisis and it is only worsening.

Key Points: 
  • Most medical experts agree we are in a global mental health crisis and it is only worsening.
  • While some companies turn to traditional methods including pharmaceuticals to solve the growing problem, others are looking to revolutionize the way we treat mental health using technology, and AI is aiming to take the driver's seat.
  • Also using technology for mental health, Talkspace, a leading virtual behavioral healthcare company recently reported third quarter 2023 financial results.
  • As PanGenomic Health says – AI and other technology may become natural health's 'smart tech partner' of the future.

Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

Retrieved on: 
Tuesday, December 19, 2023
Patient, School, Neurology, Alzheimer's disease, Drug discovery, Treatment, International Association, USC, Research, PKC, Biomedical sciences, BDNF, University, Dementia, Bangladesh Technical Education Board, NIH, Memory, Therapy, Pharmaceutical industry

NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative Disorders."

Key Points: 
  • The award was presented by Giulio Maria Pasinetti, M.D., Ph.D., Saunders Family Chair and Professor of Neurology at the Icahn School of Medicine at Mount Sinai, lead spokesperson for the event.
  • In the trial, secondary efficacy endpoints were met with statistically significant benefits, p
  • No significant cognitive decline was observed throughout the 10-month study, and persistent benefits continued at least 16 weeks beyond the final dosing.
  • Dr. Alkon discussed how, in pre-clinical studies, Bryostatin-1, MW 904, an activator of PKC epsilon – BDNF pathways, demonstrated synaptogenic, anti-apoptotic, anti-amyloid, and anti-tau tangle efficacies…."

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease

Retrieved on: 
Wednesday, October 25, 2023
Amyloid, Alzheimer's disease, Paper, Dementia, AD, Plaque, Therapy, Neuron, Data, MD, Pathology, IL-6, Cytokine, Doctor of Philosophy, Deficit spending, CNS, McGill University, DSM-IV codes, BDNF, Laboratory, Disease, Caregiver, Neurobiology of Aging, Clinical trial, Rett syndrome, SIGMAR1, Parkinson's disease, Brain, Safety, Patient, Neuroscience, Hippocampus, Central nervous system, Medical device, Pharmaceutical industry, Medical imaging, Ageing

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, today reported a new peer-reviewed publication in the journal Neurobiology of Aging, titled “Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology”, featuring the orally available small molecule ANAVEX®3-71 (AF710B).1

Key Points: 
  • Preventative treatment with ANAVEX®3-71 reduced levels of insoluble and soluble amyloid-beta as well as plaque deposition in the aging cortex and hippocampus, areas heavily impacted by AD.
  • Notably, the reduction in amyloid pathology was accompanied by a reduction in inflammatory glial activity which is connected to the disease cascade in AD and other dementias.
  • ANAVEX®3-71 treatment downregulated the proinflammatory IL-1β and IL-6 cytokines, which are known to be associated with AD.
  • This long-lasting effect was also observed in previous animal studies of ANAVEX®3-71 at advanced stages of the disease.

EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians

Retrieved on: 
Wednesday, October 4, 2023
Technology, Biotechnology, Health, Other Health, Professional Services, Research, Medical Devices, Software, General Health, Data Analytics, Genetics, Health Technology, Science, Data Management, Brain-derived neurotrophic factor, University, Crohn's & Colitis Foundation, GFAP, IBD, University of Texas at Austin, Melatonin, Interleukin 6, Biomarker, Glial fibrillary acidic protein, IL6, University of Glasgow, Crohn's disease, Patient, CRP, Physician, Conditional sentence, Inflammatory bowel disease, BDNF, Glucose, Skin, C-reactive protein, Pharmaceutical industry, Medical imaging, Cortisol, Calprotectin, CCM

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.

Key Points: 
  • Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
  • The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
  • This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
  • Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Retrieved on: 
Tuesday, August 8, 2023
Molecule, Neuron, Rat, DMT, CSE, DMT: The Spirit Molecule, Depression, Neuroplasticity, Stroke, Clinical trial, Penile spines, AGN, Pharmacokinetics, Brain, Biomarker, Signal transduction, Plasma, Ethics, Patient, Growth, Diagnosis, BDNF, Death, Imperial College London, CHDR, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study.
  • The Phase 2 human stroke trial will study an intravenous sub-psychedelic dose of DMT in patients who are hospitalized after having suffered an acute ischemic stroke.
  • Algernon consultant Dr. Rick Strassman, DMT research pioneer and author of the books DMT: The Spirit Molecule and The Psychedelic Handbook commented: “I am encouraged by the results of Algernon’s Phase 1 study in which a prolonged infusion of DMT achieved the desired pharmacokinetics.
  • “We are investigating DMT as a potential new therapeutic treatment that could have a positive impact on ischemic stroke patients worldwide.”

Soft Reboot Wellness Announces San Francisco Ketamine Infusion Therapy for MDD

Retrieved on: 
Thursday, June 29, 2023
Depression, Diet, United States National Library of Medicine, Research, Brain, Movement, Science, National library, Ketamine, DSM-IV codes, Patient, Synapse, Meditation, BDNF, Mental health, CO2, Pharmaceutical industry

Soft Reboot Wellness has announced that they are offering ketamine infusions for the treatment of major depressive disorder (MDD), anxiety, PTSD, and other mental health struggles for residents in San Francisco.

Key Points: 
  • Menlo Park, California--(Newsfile Corp. - June 29, 2023) - Soft Reboot Wellness' recent announcement gives residents of San Francisco a new therapy option for treatment-resistant depression.
  • The clinic administers low-dose ketamine once a week for four to six weeks, depending on the patient's symptoms and how well they respond to the treatment.
  • To view an enhanced version of this graphic, please visit:
    The wellness clinic's announcement coincides with a study published in the National Library of Medicine.
  • Unlike conventional antidepressants that regulate the patient's neurotransmitters by blocking reuptake, ketamine therapy builds stronger synapses and increases the production of Brain-Derived Neurotrophic Factors (BDNF), explains the clinic.